Clinical stage drug development company NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has confirmed the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB.
The news is a significant milestone in the development of EmtinB as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer’s disease.
The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.
Following the recent important announcement of securing our first HREC approval for a clinical trial, the recruitment of the first subject for the early-phase clinical trial marks another historic achievement for the company and a major milestone in developing EmtinB, as a much needed therapeutic treatment with disease modifying potential for patients with Multiple sclerosis and Alzheimer’s disease,” NeuroScientific’s Managing Director and CEO, Matt Liddelow, said.
The early-phase clinical trial will include up to 30 healthy volunteers. An important focus of this study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans and can be used to guide efficacy outcomes during future trials in patients.
